Jeff Farrow : Sure. On the MGD study, we anticipate releasing the data here in the next month and a half prior to year-end. It includes data from 2 dose types, one is BID, one is TID. And so we’ll be able to release that top-line data sometime later this year.
Operator: And our next question comes from Oren Livnat of H.C. Wainwright.
Oren Livnat: I have a couple of questions. Just to revisit this issue of the evolving payer pushback, I guess, in the immediate term. First, can you just help us understand what kind of early experiences you’re hearing about physicians, having in terms of getting their patient access early on. Do they need to fill out a letter of medical necessity now or is it just going through specialty pharmacy that’s handling all that adjudication for them on the back end so that they don’t experience any of that friction per se. And going forward, I guess obviously gross nets are going to potentially be volatile, but what about volumes? Do you suspect that if there’s an incremental pushback and reaction to your very strong volume out of the gates here, that it could actually get harder in the near term for someone to get a patient on? And what do you have to do to make sure that that doesn’t then potentially sour any doctors on the experience going forward?
Aziz Mottiwala: So I think when you think about that access right now as Jeff mentioned earlier, through the end of the year, we can expect that these folks, as they start to see volume, the payers will put some restrictions in place. We’ve seen this in pockets. I think that this is something that the doctors can navigate through. The doctors typically initiate the pa but through our focus pharmacy network, they do get some assistance in that process. But clearly, the doctor has to initiate that they have the patient records. It varies by plan what the expectations are. So in some cases, a very simple PA. In other cases, we are seeing a little bit more onerous PAs, mind you that all this coverage is not contracted right now.
So as contracts come online, we would push for a more straightforward PA to label that’s aligned with a first and only type of product. So we see that evolving over time. In terms of impact to volumes, I think what Jeff is saying is we’re continuing to see steady uptake from the physicians. We’re seeing that the doctors are getting access to the drug, they’re having great success with the drug. So we continue to see that build. I think that you have to just keep in mind that that’s more of a headwind. We don’t see it as something that would keep the prescription flat, but it does sort of give us a little bit of a headwind as we are building that acceptance with physicians. And I think the doctors are sensitive to that. They know and understand that new products take time to build coverage.
And I think it speaks to the value proposition of XDEMVY that people are committed, they’re seeing these patients, they don’t have another option. So the doctors are putting the effort in and of course our programs are there to help that process along. So we think we’ll continue to build volume steadily. But certainly, changes in policy or short-term PA adjustments can be a slight headwind as we’re ending the year here.
Oren Livnat: And just so I’m clear we’re not covered or where pushback is insurmountable is that bridging program still getting drug into patient’s hands in any and all cases essentially such that we’ll continue to see the demand reflected in the prescriptions going forward? It’s just a question of the economics that you realize in gross net.
Aziz Mottiwala: That’s exactly right.
Operator: And our next question comes from Balaji Prasad of Barclays.
Unidentified Analyst: This is McKayla on for Balaji. Thanks for taking our questions. Just thinking about your pipeline, at what point might you look to expand this further and are there any areas in particular that would be of interest?
Bobak Azamian: We do look actively at the entire eye care landscape, as you can imagine with a great early launch trajectory with a commercial platform. Eventually we want to add more products to our pipeline and to our commercial force. Right now, we can only be so modest. But with continue success, we would look to add further products and so stay tuned. Nothing to report today, but stay tuned.
